<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="widespread application, including in anti-HIV strategies [24] CRISPR–Cas9-targeting of HIV" exact="infection" post="The CRISPR–Cas9 system can be used to modify host"/>
 <result pre="previously shown when treating patients with antiviral drugs and when" exact="testing" post="RNAi antivirals in cell culture experiments [43], combining antivirals"/>
 <result pre="However, the PCR-based strategy used to detect excision strongly favors" exact="detection" post="of the short excision product over the longer non-excised"/>
 <result pre="did not support massive HIV replication and did not allow" exact="testing" post="for complete and permanent virus inactivation or virus escape."/>
 <result pre="in silico predicted and experimentally measured activity of gRNAs, when" exact="testing" post="the knockdown activity of 59 LTR-targeting gRNAs in an"/>
 <result pre="repair at the gRNA target site. Although continuation of ART" exact="treatment" post="during CRISPR–Cas9 therapy will block virus replication and prevent"/>
 <result pre="genetic diversity on CRISPR–Cas9 antiviral activity and viral escape by" exact="testing" post="the most effective dual-gRNA combinations against distinct HIV-1 isolates,"/>
 <result pre="poor predictors. Successful HIV cure attempts may therefore require elaborate" exact="testing" post="of gRNAs. Future directions CRISPR–Cas9 attack of the HIV"/>
 <result pre="monotherapies [72]. Furthermore, Dash et al. recently demonstrated that sequential" exact="treatment" post="of HIV-infected humanized mice with ‘long-acting slow-effective release’ (LASER)"/>
 <result pre="excisions and inversions observed in cellular DNA upon dual-gRNA CRISPR–Cas9" exact="treatment" post="of mammalian cells is described. When analyzing dual gRNA"/>
 <result pre="replication, but also induces the generation of escape variants. When" exact="testing" post="virus escape from different gRNAs, a strong correlation was"/>
 <result pre="of the CRISPR/Cas9 system as an intracellular defense against HIV-1" exact="infection" post="in human cells. Nat Commun2015, 6:6413.25752527 48.KaminskiR, ChenY, FischerT,"/>
 <result pre="51.YinC, ZhangT, LiF, YangF, PutatundaR, YoungWB, KhaliliK, HuW, ZhangY: Functional" exact="screening" post="of guide RNAs targeting the regulatory and structural HIV-1"/>
 <result pre="viral escape is described. It is shown that combinatorial CRISPR–Cas9" exact="treatment" post="can cure T cells infected by distinct HIV isolates,"/>
 <result pre="expressing Cas9 and a multiplex of gRNAs. This in vivo" exact="treatment" post="resulted in the editing and removal of proviral DNA."/>
 <result pre="humanized mice. Nat Commun2019, 10:2753.31266936 This report describes that sequential" exact="treatment" post="of HIV-infected humanized mice with ‘long-acting slow-effective release’ (LASER)"/>
</results>
